Lowering the IOP remains the only proven method to prevent the development or slow the progression of glaucomatous optic neuropathy. Interestingly, a significant proportion of the treatment groups in the Early Manifest Glaucoma Trial (EMGT), the Collaborative Initial Glaucoma Treatment Study (CIGTS), and the Collaborative Normal-Tension Glaucoma Study (CNTGS) experienced glaucomatous progression despite achieving the targeted decrease in IOP.

Although the cause of disease progression despite seemingly adequate IOP lowering is likely multifactorial, abnormalities in ocular perfusion have become a prime consideration. Vascular risk factors for glaucomatous progression implicate abnormal or insufficient blood flow to the optic nerve as a likely contributor to the disease process. This article describes novel diagnostic techniques as well as potential therapies related to ocular blood flow and glaucoma care.

DIAGNOSING ABNORMAL BLOOD FLOW

Low ocular perfusion pressure (OPP) may be used to determine whether abnormal microvascular flow is likely to occur at the level of the optic nerve. OPP is defined as the mean arterial pressure minus the IOP. Epidemiologic studies have identified low OPP as an independent risk factor for the development and progression of glaucoma.

Investigators have studied the potential of several advanced imaging modalities to uncover an ocular blood flow abnormality related to glaucomatous disease. Color Doppler imaging uses Doppler ultrasound to obtain quantitative measurements of the ophthalmic arterial circulation. This relatively noninvasive technique involves placing an ultrasound probe over a patient’s closed eyelid. Based on diastolic flow velocities, ophthalmic arterial blood flow is measured in...
“Advances in diagnostic imaging, particularly with novel OCT devices, promise to allow physicians to reliably measure optic nerve blood flow in the future.”

terms of ophthalmic arterial resistance (OA resistance index), Galassi et al.⁹ found that newly diagnosed glaucoma patients were six times more likely to suffer progressive disease when the OA resistivity index measured higher than 0.78 compared to patients with an OA index lower than 0.78 (P < .001). Laser Doppler flowmetry¹⁰ and laser speckle flowgraphy¹¹ have also been shown to be capable of detecting differences in optic nerve blood flow in glaucomatous and nonglaucomatous eyes. Unfortunately, the use of these methods for measuring the blood flow of small-caliber optic nerve vessels is limited by rather modest reliability indices.

Recently, Jia and colleagues reported on the use of optical coherence tomography (OCT) techniques to measure optic disc perfusion.¹² These techniques require the use of a high-speed OCT device (a repetition rate of 100-kHz axial scans) and a novel split-spectrum amplitude-decorrelation angiography algorithm to measure microvascular blood flow. This algorithm allows the detection of variable signal amplitudes returning from nonstatic tissues. Higher variability in signal amplitude leads to greater decorrelation of detected signals and occurs secondary to higher microvascular red blood cell flow rates. The degree of decorrelation may be quantified as the disc flow index, which is defined as the average decorrelation value within a three-dimensional volumetric scan of the optic disc. The investigators reported high intravist repeatability and intervisit reproducibility indices with 100% sensitivity/specificity for differentiating normal optic discs from glaucomatous ones using a flow index cutoff of 0.1515. Importantly, disc flow index was found to correlate with visual field pattern standard deviation in patients with glaucoma (R² = 0.752, P = .001), indicating a relationship with functional deficit. The advantages of OCT angiography include its noninvasive nature and its ability to quantify microvascular flow in the optic nerve with high repeatability (Figure). The same investigators have also measured peripapillary retinal blood flow using a high-speed (70 kHz) commercial OCT device (RTVue-XR Avanti; Optovue) with similarly favorable results (e-mail communication, August 4, 2014).

**THERAPEUTIC OPTIONS**

Considering the role of ocular blood flow in glaucoma care requires practical therapeutic options to allow for clinical decision making. Feke et al prospectively evaluated the effect of brimonidine 0.15% on retinal hemodynamics in glaucomatous eyes with retinal vascular dysregulation as determined by laser Doppler flowmetry.¹³ The group found that brimonidine significantly improved the impaired retinal vascular autoregulation in these patients, presumably through its interaction with the nitric oxide signaling cascade and modulation of retinal vascular tone. Using laser Doppler flowmetry, Kimura and colleagues investigated the effect of topical unoprostone on circulation in the optic nerve head of nonglaucomatous eyes and those with normal-tension glaucoma.¹⁴ The investigators found that, compared to baseline values, the mean blood flow and velocity values increased in both groups 2 hours after the topical instillation of unoprostone (P < .05).

In preliminary animal studies, Rho kinase inhibitors have also been shown to improve optic nerve blood flow, presumably via relaxation of the vascular endothelial smooth muscle.¹⁵,¹⁶ These agents are not yet commercially available but are in clinical trials for approval by the FDA.

Topical β-blocker therapy may diminish optic nerve head blood flow in susceptible individuals. Hayreh et
al found that patients with normal-tension glaucoma who were treated with topical timolol twice daily were at increased risk of nocturnal arterial hypotension that potentially contributed to higher rates of visual field progression compared to subjects not treated with this agent \( (P = .0003) \). This potentially adverse effect of topical β-blockers may have contributed to the increased risk of visual field deterioration compared to subjects treated with brimonidine, as reported in the Low-Pressure Glaucoma Treatment Study (LoGTS). \(^{18}\)

Januleviciene and colleagues reported on the beneficial effects of trabeculectomy surgery on ocular hemodynamic parameters in patients with pseudoexfoliative and open-angle glaucoma. \(^{19}\) In the study, a significant improvement in OPP and color Doppler imaging parameters was realized in the postoperative period compared to preoperatively.

**CLINICAL CONSIDERATIONS**

Advances in diagnostic imaging, particularly with novel OCT devices, promise to allow physicians to reliably measure optic nerve blood flow in the near future. Currently available therapeutic options such as topical brimonidine, topical unoprostone, and trabeculectomy appear to benefit optic nerve blood flow, whereas topical β-blockers may be disadvantageous in susceptible individuals. Topical Rho kinase inhibitors may also prove to be a therapeutic option. Clinicians’ ability to diagnose and treat blood flow abnormalities in the optic nerve head may allow them to decrease the risk of glaucomatous progression in individuals with an IOP-independent component to their disease process.

Ahmad A. Aref, MD, is an assistant professor of ophthalmology at the Illinois Eye & Ear Infirmary, University of Illinois at Chicago School of Medicine, Chicago. He acknowledged no financial interest in the products or companies mentioned herein. Dr. Aref may be reached at (312) 996-7030; ahmadaref@gmail.com.

Yali Jia, PhD, is a research associate professor at the Casey Eye Institute, Oregon Health & Science University, Portland, Oregon. She has a financial interest in Optovue.

David Huang, MD, PhD, is a professor at the Casey Eye Institute, Oregon Health & Science University, Portland, Oregon. He has a financial interest in Optovue, and he receives royalties on an OCT patent licensed by the Massachusetts Institute of Technology to Carl Zeiss Meditec and LightLab Imaging. Dr. Huang may be reached at (503) 494-3000.

---


---

**SHARE YOUR FEEDBACK**

Would you like to comment on an author’s article?

Do you have an article topic to suggest?

Do you wish to tell us how valuable *Glaucoma Today* is to your practice?

We would love to hear from you.

Please e-mail us at gtletters@bmctoday.com with any thoughts, feelings, or questions you have regarding this publication.